TrueCAGR

Sun Pharmaceutical Industries Ltd.

NSE: SUNPHARMABSE: 524715ISIN INE044A01036Face value ₹1standalone
₹1,885
−0.94% · 2026-11-20 · 52-wk ₹1,589–₹2,001
Source: BSE filings · Financials to FY2026 · 8 years of history · Data last updated: results filed 30 Oct 2026, prices to 20 Nov 2026 · How we calculate thisconsolidatedstandalone
Section 02 · Synthesis

What stands out?

The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.

StrengthConcernWatchContext
WatchTalking point

Cash conversion trending down

Cash conversion (CFO ÷ profit) has averaged 1.21× over the last 3 profit-making years versus 1.98× before that.

Importance 64 / 95 · cash quality

StrengthTalking point

Debt reduced

Total debt is down from ₹9,893 to ₹4,082 over 7 years (58.7% lower); debt-to-equity moved 0.22× → 0.05×.

Importance 63 / 95 · financial health

WatchTalking point

Profit lagging revenue

Revenue grew 11.2% but profit grew 5.0%, so the company kept less of each rupee of revenue as profit.

Revenue growth+11.2%Net profit growth+5.0%

Importance 62 / 95 · growth

WatchTalking point

Volatile earnings

Profit has swung sharply over 7 years (from ₹2,272 to ₹11,509) — one year is a weak guide to the earnings power.

Importance 58 / 95 · growth

Section 03 · The company

Who is this company?

Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.

Market cap
₹4.52 L cr
FY2026 revenue
₹20,755 cr
FY2026 net profit
₹2,623 cr
Net worth
₹22,371 cr
Total debt
₹13,420 cr
EPS (basic)
₹10.90
Listed
NSE · BSE
Reporting
Ind-ASApr–Mar

Peer set used on this page: 12 pharmaceuticals.

Section 04 · Business performance

Is the business growing?

Revenue grew 10.5% a year over 7 years, from ₹10,303 cr in FY2019 to ₹20,755 cr in FY2026. Net profit grew 18.1% a year over the same period.

Revenue & net profit — FY19 to FY26₹ crore · consolidated
₹'000 cr08152330035REVENUENET PROFIT10k817FY1913k3,211FY2013k2,140FY2116k-100FY2221k1,691FY2320k2,858FY2423k4,283FY2521k2,623FY26
RevenueNet profit
Watch

Revenue grew 11.2% but profit grew 5.0%, so the company kept less of each rupee of revenue as profit.

Rule PROFIT_SLOWER_THAN_REVENUE

Revenue growth per year
+10.5%over 7 years (FY19–FY26)
Revenue growth
−9.8%vs last year
Net profit growth
−38.7%vs last year
Change in net profit since FY19
+221%

Profit has swung sharply over 7 years (from ₹2,272 to ₹11,509) — one year is a weak guide to the earnings power.

Over 7 years profit compounded at 20.0% a year while revenue compounded at 10.5% a year — though FY2023 saw a one-off step-change of 151% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.

Revenue has compounded at 10.5% a year over 7 years (₹29,066 → ₹58,462) — steady rather than rapid.

Section 05 · Recent activity

What changed recently?

In Q2 FY27 (Jul–Sep 2026), revenue was ₹16,199 cr (up 11.9% on the same quarter last year) and net profit ₹1,995 cr (down 36.2%).

Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.

Concern

Q2 FY27 net profit was ₹1,995 cr, down 36.2% from ₹3,125 cr a year earlier.

Rule QTR_PROFIT_GROWTH_YOY

Watch

Q2 FY27 net profit declined 36.2% vs the same quarter last year, reversing the growth seen in the two preceding quarters (+25.8% and +26.5%).

Rule QTR_TREND_REVERSAL

Watch

Q2 FY27 net profit declined 36.2% while revenue grew 11.9% vs the same quarter last year — a gap of 48.0 percentage points.

Rule QTR_PROFIT_VS_REVENUE_GROWTH

A. Quarterly results

Latest quarters — Q3 '25 to Q2 '27₹ crore · consolidated
₹'000 cr05101520024REVENUENET PROFIT14k2,913Q3 '2513k2,154Q4 '2514k2,293Q1 '2614k3,125Q2 '2616k3,381Q3 '2615k2,710Q4 '2615k2,901Q1 '2716k1,995Q2 '27
RevenueNet profit
QuarterRevenueYoYNet profitYoYNet margin
Q3 FY2513,675+10.5%2,913+13.8%21.3%
Q4 FY2512,959+8.1%2,154−19.0%16.6%
Q1 FY2613,851+9.5%2,293−19.8%16.6%
Q2 FY2614,478+8.9%3,125+2.9%21.6%
Q3 FY2615,521+13.5%3,381+16.1%21.8%
Q4 FY2614,612+12.8%2,710+25.8%18.5%
Q1 FY2715,300+10.5%2,901+26.5%19.0%
Q2 FY2716,199+11.9%1,995−36.2%12.3%

B. TTM snapshot

Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters

Revenue
₹61,631 crTTM
EBITDA
₹20,343 crTTM
EBIT
₹17,338 crTTM
PBT
₹15,037 crTTM
Net profit
₹10,987 crTTM

C. Corporate actions

7 Jul 2026DividendFinal Dividend - Rs. - 5.0000 — ₹5.00/share
5 Feb 2026DividendInterim Dividend - Rs. - 11.0000 — ₹11.00/share
7 Jul 2025DividendFinal Dividend - Rs. - 5.5000 — ₹5.50/share
6 Feb 2025DividendInterim Dividend - Rs. - 10.5000 — ₹10.50/share
12 Jul 2024DividendFinal Dividend - Rs. - 5.0000 — ₹5.00/share
9 Feb 2024DividendInterim Dividend - Rs. - 8.5000 — ₹8.50/share
28 Jul 2023DividendFinal Dividend - Rs. - 4.0000 — ₹4.00/share
8 Feb 2023DividendInterim Dividend - Rs. - 7.5000 — ₹7.50/share
19 Aug 2022DividendFinal Dividend - Rs. - 3.0000 — ₹3.00/share
9 Feb 2022DividendInterim Dividend - Rs. - 7.0000 — ₹7.00/share
23 Aug 2021DividendFinal Dividend - Rs. - 2.0000 — ₹2.00/share
9 Feb 2021DividendInterim Dividend - Rs. - 5.5000 — ₹5.50/share
19 Aug 2020DividendFinal Dividend - Rs. - 1.0000 — ₹1.00/share
17 Feb 2020DividendInterim Dividend - Rs. - 3.0000 — ₹3.00/share
20 Aug 2019DividendDividend - Rs. - 2.7500 — ₹2.75/share
17 Sept 2018DividendDividend - Rs. - 2.0000 — ₹2.00/share
18 Sept 2017DividendDividend - Rs. - 3.5000 — ₹3.50/share
8 Sept 2016DividendDividend - Rs. - 1.0000 — ₹1.00/share
14 Jul 2016BuybackBuy Back of Shares
21 Oct 2015DividendDividend - Rs. - 3.0000 — ₹3.00/share
11 Sept 2014DividendDividend - Rs. - 1.5000 — ₹1.50/share
19 Sept 2013DividendDividend - Rs. - 2.5000 — ₹2.50/share
29 Jul 2013Bonus issueBonus issue 1:1 — 1:2
14 Aug 2012DividendInterim Dividend - Rs. - 4.2500 — ₹4.25/share
2 Sept 2011DividendDividend - Rs. - 3.5000 — ₹3.50/share
Section 06 · Business performance

Is it becoming more profitable?

EBITDA margin was 31.8% in FY2026, against 29.4% in FY2019. ROE was 11.2% and ROCE 14.9% in FY2026.

Margins — FY19 to FY26% of revenue · consolidated
-5%0%5%10%15%20%25%30%35%31.8%12.4%FY19FY20FY21FY22FY23FY24FY25FY26
EBITDA marginNet margin

Margin and return trends are shown above.

EBITDA margin now
31.8%
8-year range
24.1–33.7%
ROE FY2026
11.2%
ROCE FY2026
14.9%
Section 07 · Financial health

Is financial health improving?

Debt-to-equity was 0.60x in FY2026, against 0.26x in FY2019; interest coverage 5.58x. Operating cash flow was 2.48x net profit.

Net worth — FY19 to FY26₹ crore · consolidated
₹'000 cr010203023kFY1924kFY2025kFY2125kFY2224kFY2324kFY2424kFY2522kFY26
Net worth (shareholders' funds)
Watch

Cash conversion (CFO ÷ profit) has averaged 1.21× over the last 3 profit-making years versus 1.98× before that.

Rule CASH_CONVERSION_DETERIORATING

Operating cash flow vs net profit₹ crore · FY21–FY26
0k3k5k8k2k2kFY218k-100FY225072kFY23-2923kFY244k4kFY257k3kFY26
Operating cash flowNet profit
Total debt
₹13,420 cr
Operating cash flow ÷ net profit
2.48×FY2026
Free cash flow
₹4,987 cr
Current ratio
2.56×

Total debt is down from ₹9,893 to ₹4,082 over 7 years (58.7% lower); debt-to-equity moved 0.22× → 0.05×.

Operating cash flow has matched or exceeded reported profit in 5 of the last 6 profit-making years (latest 1.08×).

Free cash flow has been positive in 6 of the last 6 years.

Section 08 · Relative position

How does it compare with peers?

Within its 12-company Pharmaceuticals peer group, it ranks 6 of 12 on return on equity and 2 of 12 on EBITDA margin. Its P/E of 41.2 compares with a peer median of 45.3.

Ranked against 12 pharmaceuticals (FY2026, consolidated). No peer-relative rule fired for this company.

Revenue growth

SUNPHARMA · 8th of 12 · set median 14.8%

GLENMARK27.5%LUPIN23.1%LAURUSLABS22.7%TORNTPHARM21.4%MANKIND17.0%ZYDUSLIFE16.8%DIVISLAB12.8%SUNPHARMA11.2%BIOCON10.9%AUROPHARMA6.1%DRREDDY3.2%CIPLA2.2%

EBITDA margin

SUNPHARMA · 2nd of 12 · set median 28.7%

DIVISLAB37.4%SUNPHARMA33.7%ZYDUSLIFE33.1%LUPIN33.1%TORNTPHARM31.9%GLENMARK29.6%MANKIND27.8%LAURUSLABS26.9%CIPLA24.0%DRREDDY23.2%BIOCON22.4%AUROPHARMA21.8%

Return on equity

SUNPHARMA · 6th of 12 · set median 14.4%

LUPIN26.9%ZYDUSLIFE18.3%LAURUSLABS17.7%TORNTPHARM17.0%DIVISLAB16.2%SUNPHARMA14.7%GLENMARK14.1%MANKIND12.5%CIPLA11.7%DRREDDY11.5%AUROPHARMA9.9%BIOCON1.1%

P/E ratio

SUNPHARMA · 5th of 12 · set median 45.3×

LUPIN17.6×AUROPHARMA26.2×ZYDUSLIFE28.1×CIPLA40.1×SUNPHARMA41.2×DRREDDY42.1×MANKIND48.5×GLENMARK51.5×TORNTPHARM75.8×DIVISLAB88.3×LAURUSLABS93.0×BIOCON174.3×
P / E
41.2×TTM to Sept 26
P / B
5.4×latest book
P / S
7.3×TTM sales
Earnings yield
2.4%TTM to Sept 26

On the trailing twelve months. Last full year: P/E 39.3× · P/S 7.5× · ROE 14.7%.

Section 09 · The stock

How has the stock performed?

The share price is up 6.1% over 1 year, up 56.9% over 3 years (16.2% a year) and up 138% over 5 years (19.0% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 5.8% below its 52-week high.

Adjusted close — 2020-01 to 2026-11₹ per share · split / bonus adjusted
0k₹1,8852020202120222023202420252026
Context

Over 5 years profit compounded at 38.3% a year while the stock returned 19.0% a year — but FY2021 profit (₹2,272) was well below the through-cycle level (~₹6,342), so this rate is inflated by the recovery from a low base.

Rule STOCK_LAGGED_EARNINGS · recovery

Business vs stock — 5-year compound annual rate
Net profit38.3%/yrShare price19.0%/yr
1-year return
+6.1%
3-year return
+56.9%
5-year return
+138.4%
From 52-wk high
−5.8%
Section 10 · Technical data

What does the technical data say?

Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.

vs 50-day avg
Above₹1,819
vs 200-day avg
Above₹1,820
RSI (14)
62.3neutral
MACD histogram
8.4
From 52-wk high
−5.8%
From 52-wk low
+18.6%
30-day volatility
15.7%ann.
6-month return
+0.1%
RSI (14) · 0–10062.3 — neutral
0305070100OVERSOLDOVERBOUGHT62.3
Section 11 · Open questions

What should I investigate further?

Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.

  • Watch
    Cash conversion trending down
    Cash conversion (CFO ÷ profit) has averaged 1.21× over the last 3 profit-making years versus 1.98× before that.
    CASH_CONVERSION_DETERIORATING · conviction 64
  • Watch
    Profit lagging revenue
    Revenue grew 11.2% but profit grew 5.0%, so the company kept less of each rupee of revenue as profit.
    PROFIT_SLOWER_THAN_REVENUE · conviction 62
  • Watch
    Volatile earnings
    Profit has swung sharply over 7 years (from ₹2,272 to ₹11,509) — one year is a weak guide to the earnings power.
    EARNINGS_VOLATILE · conviction 58
  • Watch
    Reported profit carries a one-off
    FY2026 pre-tax profit includes a ₹1,307 exceptional charge (8.6% of PBT) — the underlying trend differs from the reported number.
    PROFIT_INCLUDES_EXCEPTIONALS · conviction 39
  • Cash-flow-statement facts are unavailable for FY2019, FY2020 — those filings predate SEBI's Cash Flow Statement disclosure requirement. All other loaded years carry full P&L, balance sheet and cash-flow data.
Section 12 · Reference

The numbers

The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.

Income & balance sheet — ₹ crore, consolidated
MetricFY19FY20FY21FY22FY23FY24FY25FY26
Revenue10,30312,53212,80315,58620,81220,27523,00320,755
Total income11,57514,04312,95316,54421,09120,74123,37321,174
EBITDA3,0284,2233,0863,8656,7526,0537,1626,600
Profit before tax7193,2532,1533071,7413,4505,0313,794
Net profit8173,2112,140−1001,6912,8584,2832,623
EPS (₹)3.413.48.9−0.47.011.917.810.9
Net worth22,84424,39625,04024,58823,74823,69424,34022,371
Total debt5,8515,7626,4864,8697,59311,04710,95413,420
Operating cash flow——1,7377,636507−2924,1996,501
Free cash flow——9866,833−447−1,0273,5454,987
Key ratios — consolidated
RatioFY19FY20FY21FY22FY23FY24FY25FY26
Growth
Revenue growth YoY—21.62.221.733.5-2.613.5-9.8
Profit growth YoY—293.2-33.4——69.149.8-38.7
Profitability
EBITDA margin %29.433.724.124.832.429.931.131.8
Net margin %7.122.916.5-0.68.013.818.312.4
Return on equity %3.613.68.7-0.47.012.017.811.2
Return on capital %8.612.48.18.216.913.516.914.9
Leverage & cash
Debt to equity0.260.240.260.200.320.470.450.60
Cash flow ÷ profit——0.81—0.30-0.100.982.48
Current ratio0.841.071.450.961.973.361.032.56
Financials: BSE Integrated Filing inline XBRL (SEBI taxonomy), normalised to standard metric keys. Prices: end-of-day — history loaded from NSE end-of-day files, new days from the BSE bhavcopy; raw OHLC preserved; a corporate-action factor produces the adjusted series. The insight engine writes factual observations from fixed rules — it does not make recommendations. Not investment advice.